VVS and rectal positive NAATs, the AC2 Reactive Light Units levels were equivalent, suggesting active infection at both sites. Discussion/conclusion In this sample of women with no rectal symptoms, the rectum was the most prevalent site for chlamydia infection, and rectal swabs found significantly more infections than VVS. There was no association with reported anal sex indicating sexual risk history is unreliable for targeted screening in women.
Background/introduction Few data are available to guide the best time to perform a test of cure using nucleic acid amplification tests (NAATs) following treatment for chlamydia (CT) and gonorrhoea (NG). Aim(s)/objectives The association between the type of infection, organism load, site of infection and treatment were compared to the time for the NAAT to become negative after treatment.
Methods Individuals who had a positive NAAT test for CT and/ or NG were eligible. Self-taken specimens from the site of infection were collected at 8 time points.The time to first negative test following treatment was examined using survival analysis techniques. Results 102 men (87 MSM) and 52 women were recruited to the study (84 NG, 71 CT infections) . 28 participants with NG and 16 with CT were lost to follow up. On day 0, 20 participants diagnosed with NG and 8 diagnosed with CT had negative tests. Median time to negativity for NG infection was 2 days (IQR 1-5) and for CT infection was 4 days (IQR 2-5). At day 14 after treatment 92% of participants were CT negative, and 84% NG negative.All tests were negative by day 35 for both infections. Discussion/conclusion This study provides valuable data in determining the time to test of cure for CT and NG infections. Site of infection may have an effect on time to clearance of infection, with pharyngeal NG infections and vaginal CT infections taking longer to clear than other sites.The results of this study will help guide clinicians to the timing for test of cure. Background/introduction Trichomonas vaginalis is prevalent in patients of black ethnicity in our south London population. Nucleic acid amplification testing (NAAT) is the diagnostic gold standard, and first-line treatment with metronidazole or tinidazole regimens thought to achieve comparable cure rates >90%. Test of cure (TOC) is recommended if symptoms persist following treatment, but this overlooks persistent asymptomatic infection and optimal timing and testing modality are uncertain. Aim(s)/objectives To estimate clinical cure and TV eradication rates in a large cohort of T. vaginalis cases. Methods All positive T. vaginalis NAAT results (TV TMA, Hologic) were identified between January 2013 and September 2015. Data were collected from our electronic patient record system, including clinical features, treatment regimen and TOC results, if performed. Results 557 cases were identified in 500 patients (78.2% female; 82.2% Black African/Caribbean/mixed ethnicity; 8.8% HIV+). Infection was symptomatic in 47.3% (53.7% females, 24.5% males). Baseline wet mount microscopy was positive in 65.6%. TOC was performed in 72.4% (median time to TOC 4.1 weeks, IQR 2.3-7.6 weeks). 77.2% demonstrated parasitological clearance following a single treatment course. Cure rates were 70-80 for all regimens, significantly higher in males (85.5% vs 66.9%, p < 0.01). Discussion/conclusion We see a significant asymptomatic, microscopy-negative burden of T. vaginalis infection. Lower clearance rates in women suggest azole-resistant strains may be prevalent. Based on NAAT results, cure rates are lower than expected, and relatively constant TMA positivity rate beyond 2 weeks suggests treatment failure is responsible rather than re-infection or timing of TOC. Further UK studies on treatment efficacy and molecular epidemiology are warranted. .73] were also associated with acceptability. Discussion Although nearly half of MSM would not actively pursue HPV vaccination, the vast majority would accept the vaccine if recommended by HCPs. MSM need to be informed about HPV to appraise the benefits of HPV vaccination for their health. In order to achieve optimal uptake, vaccine promotion campaigns need to focus on MSM that do not access sexual health clinics and those unwilling to disclose their sexual orientation. Background/introduction We introduced HPV4 vaccination for younger MSM under 27 years into our sexual health services in 2012. We report on the attendance behaviour, clinical outcomes, completion rates and factors associated with vaccination completion in our cohort. Aims (1) To deliver 3 dose HPV4 vaccination to younger MSM. (2) To increase engagement and STI testing by younger MSM at integrated sexual health services. Methods HPV4 vaccine was offered at Time 0, 2-4 and 6-12 months, with STI testing, clinic call/recall, alongside care and support as appropriate. We conducted a retrospective electronic case note (EPR) review of all eligible MSM at end 2015. Completion rates are censored at 1 year. Results 893/930 (96%) offered vaccine accepted 1 st dose. Discussion/conclusion We observed 3 dose completion rates commensurate with outcomes expected from a catch up vaccination programme. Completion was associated with older age, HIV infection, prior known HPV infection, self-identifying homosexual men and non-white british ethnicities. We observed high rates of STI testing and infection in this cohort. Delivering HPV vaccination within sexual health care services is an effective engagement strategy for young MSM. 
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